Inventiva (NASDAQ:IVA) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Posted by Francis Steltz on Jul 20th, 2026

Cantor Fitzgerald started coverage on shares of Inventiva (NASDAQ:IVA – Free Report) in a research report sent to investors on Friday, MarketBeat Ratings reports. The firm issued an overweight rating on the stock.

IVA has been the topic of several other research reports. Truist Financial started coverage on shares of Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Finally, Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $16.56.

Read Our Latest Stock Analysis on Inventiva

Inventiva Stock Performance

Shares of NASDAQ IVA opened at $4.62 on Friday. Inventiva has a 12 month low of $2.85 and a 12 month high of $7.98. The company has a 50-day simple moving average of $4.36 and a 200-day simple moving average of $5.32.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IVA. Creative Planning purchased a new position in shares of Inventiva during the 2nd quarter worth about $32,000. Virtu Financial LLC acquired a new stake in shares of Inventiva during the 4th quarter worth $60,000. XTX Topco Ltd acquired a new stake in shares of Inventiva during the 4th quarter worth $84,000. Cerity Partners LLC purchased a new position in shares of Inventiva in the 4th quarter worth $93,000. Finally, NewEdge Advisors LLC purchased a new position in shares of Inventiva in the 3rd quarter worth $116,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

(Get Free Report)

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.